Armis Named Leader in GigaOm Radar Report for Operational Technology (OT) Security
10.7.2023 15:00:00 EEST | Business Wire | Press release
Armis, the leading asset visibility and security company, today announced that it has been named a leader in the GigaOm Radar Report for Operational Technology (OT) Security.
“We’re proud to be recognized by GigaOm as a leader in operational technology security,” said Nadir Izrael, CTO and Co-founder, Armis. “It’s critical to secure the hardware and software systems that control physical devices and the industrial processes that our society depends on. Our mission is to ensure the availability, reliability and safety of these industrial control systems by mitigating cybersecurity risks that could otherwise lead to system failures, operational disruptions or physical damages.”
Within the GigaOm Radar for OT Security, Armis is:
- positioned in the Leaders ring, recognized for being a highly scalable platform and for the solution's strong vulnerability management features, practical AI and dynamic segmentation.
- housed in the Innovation/Platform Play quadrant. The Innovation positioning highlights technical innovation while the Platform Play displays a broader platform focus and commitment to a comprehensive feature set.
- recognized as a Fast Mover when evaluating strategy and pace of innovation in this forward-looking assessment plotting the current projected positioning of each vendor over a 12- to 18-month window.
“Of all the vendors we looked at, Armis provided the fastest time to value and the widest coverage. Because it’s cloud-based, Armis is also simple to manage. All these factors made it easy to choose Armis, frankly,” said Mike Towers, Chief Security and Trust Officer, Takeda Pharmaceuticals. “Thanks to Armis, we’ve already uncovered a series of potential cyber risks. Without the Armis deployment, we never would have known they existed. It has already paid for itself.”
Armis is rated exceptional in the report for its:
- SaaS solution which serves large enterprises and manufacturers
- AI technologies for threat detection and rendezvous capabilities which GigaOm considered differentiating and critical in this sector
- product evaluation metrics, specifically scalability and compliance.
Additionally, Armis was recognized as the only OT vendor with FedRAMP Moderate ATO, ISO 27001, ISO 28018 Best Practices and SOC 2 Type II certifications.
“A key differentiator for Armis is its excellent knowledge base, which contains critical information about the billions of devices under its monitoring umbrella, including both the device profile and the expected behaviors of that device,” said Chris Ray, Research Analyst at GigaOm. “This solution is able to leverage that information to quickly identify unusual or abnormal conditions that legacy security tools (like an intrusion detection system, or IDS) would not be able to detect. Armis has a strong focus on healthcare, manufacturing and the public sector. From our point of view, the product complements existing OT security solutions.”
“From an overall security perspective, visibility into the manufacturing area was a big thing for us,” said Shem Stephens, Security Engineer at Colgate-Palmolive. “We needed a tool to see what our plants are doing in order to better support them in terms of their security posture— and Armis fit the bill perfectly. Our auditing team uses Armis to look into areas of opportunity at our plants. And systems engineers use Armis to see when a programmable logic controller (PLC) was last changed out. They have that information at their fingertips now. As our leadership continues to collaborate with Armis leadership, we can create these unique use cases that provide tremendous benefits for specific teams or individuals.”
To read the full GigaOm Radar Report for Operational Technology (OT) Security, please visit: https://www.armis.com/analyst-reports/gigaom-radar-for-ot-security/
For the Armis blog surrounding this report, go to: https://www.armis.com/blog/armis-named-leader-in-gigaom-radar-report-for-operational-technology-ot-security/
Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230710189829/en/
Contact information
Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
